# RIVFLOZA - (EQ 80MG BASE/0.5ML, EQ 128MG BASE/0.8ML, EQ 160MG BASE/ML ; Solution)

| | | | |
|---|---|---|---|
| **Generic Name** | NEDOSIRAN SODIUM | **Innovator** | Novo Nordisk |
| **Dosage** | EQ 80MG BASE/0.5ML, EQ 128MG BASE/0.8ML, EQ 160MG BASE/ML ; Solution | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | None | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | RIVFLOZA is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ? 30 mL/min/1.73 m2. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.